<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">Preclinical investigations proved the benefit of lopinavir/ritonavir combination therapy against COVID-19. Lopinavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and in a fixed-dose combination with ritonavir, it is a potent CYP3A4 inhibitor that boosts lopinavir concentrations, could block the main protease of SARS-CoV-1, and inhibits viral replication (
 <xref rid="bib47" ref-type="bibr">Ratia etÂ al., 2008</xref>). This combination is being considered as a remedy for COVID-19, but complementary research has failed to confirm the results (
 <xref rid="bib77" ref-type="bibr">Cao et al., 2020</xref>).
</p>
